Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

How I manage cirrhosis in a busy outpatient clinic? The P.O.R.T.A.L.V.E.I.N. mnemonic.

The American journal of gastroenterology·2026
Same author

Non-absorbable antibiotics worsen alcohol-associated liver disease in gastric acid-suppressed mice.

Gut microbes·2026
Same author

Operationalizing a walking exercise prescription based on 6-minute walk test results.

Research square·2026
Same author

Preoperative Diagnosis of Idiopathic Myointimal Hyperplasia of Mesenteric Veins in a Post-Liver Transplant Patient.

Gastro hep advances·2026
Same author

Frailty 1 year after liver transplant is associated with long-term mortality: From the Functional Assessment in Liver Transplantation (FrAILT) Study.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026
Same author

The Liver Frailty Index improves mortality risk prediction for GEMA-Na.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2026

Related Experiment Video

Updated: Jun 14, 2026

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

ACG Clinical Guideline: Hepatic Encephalopathy.

Jasmohan S Bajaj1, Sofia S Jakab2, Arun B Jesudian3

  • 1Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.

The American Journal of Gastroenterology
|March 3, 2026
PubMed
Summary

Hepatic encephalopathy (HE) significantly impacts cirrhosis patients, often leading to inadequate transplant prioritization. This guideline offers 24 evidence-based recommendations for HE diagnosis, management, and prevention.

Keywords:
Bristol Stool scalecaregiver burdencirrhosiscognitive testingdisorder of gut-brain axisliver transplantreadmission

More Related Videos

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Related Experiment Videos

Last Updated: Jun 14, 2026

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

Area of Science:

  • Gastroenterology
  • Hepatology
  • Clinical Practice Guidelines

Background:

  • Hepatic encephalopathy (HE) is a serious complication of cirrhosis, affecting patients, families, and healthcare systems.
  • Current liver transplant criteria may not adequately reflect HE progression and its impact on quality of life.
  • This highlights a gap in prioritizing patients for transplantation despite significant functional impairment.

Purpose of the Study:

  • To provide comprehensive, evidence-based recommendations for the diagnosis of hepatic encephalopathy.
  • To outline effective management strategies for patients with hepatic encephalopathy.
  • To present guidelines for the prevention of hepatic encephalopathy in cirrhosis patients.

Main Methods:

  • Development of 24 recommendations based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework.
  • Systematic review and appraisal of evidence quality for each recommendation.
  • Inclusion of key concepts for statements not assessed by the GRADE process.

Main Results:

  • The guideline presents 24 distinct recommendations covering diagnosis, management, and prevention of hepatic encephalopathy.
  • Evidence quality was rigorously assessed using the GRADE methodology.
  • Key concepts are provided to supplement the GRADE-assessed statements.

Conclusions:

  • Hepatic encephalopathy requires a structured approach to diagnosis, management, and prevention in cirrhosis.
  • The guideline aims to improve patient care and potentially inform transplant prioritization.
  • Adherence to these recommendations can mitigate the burden of hepatic encephalopathy.